SCHEMBL4587753

SCHEMBL4587753

O=C(NCC1CC(=O)N(c2ccc(N3CCCCC3=O)cc2)C1)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.54
ALDH1A1 P00352 5/20 0.51
HSD17B10 Q99714 1/20 0.51
MAPT P10636 3/20 0.50
LMNA P02545 2/20 0.50
GFER P55789 1/20 0.50
TSHR P16473 1/20 0.49
RECQL P46063 1/20 0.49
F10 P00742 1/20 0.48
HPGD P15428 3/20 0.48
CYP1A2 P05177 2/20 0.48
RAB9A P51151 2/20 0.48
POLB P06746 2/20 0.47
MEN1 O00255 1/20 0.47
BLM P54132 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NPC1 O15118 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4593361 0.89 LMNA (0.65) PRMT5ALDH1A1HSD17B10MAPTLMNA
SCHEMBL5644079 0.89 MAPT (0.65) PRMT5ALDH1A1HSD17B10MAPTLMNA
SCHEMBL5641374 0.89 LMNA (0.53) PRMT5ALDH1A1HSD17B10MAPTLMNA
SCHEMBL5640206 0.89 HSD17B10 (0.56) PRMT5ALDH1A1HSD17B10MAPTLMNA
SCHEMBL4586513 0.88 BCHE (0.50) PRMT5ALDH1A1HSD17B10MAPTLMNA
SCHEMBL4594264 0.88 LMNA (0.67) PRMT5ALDH1A1HSD17B10MAPTLMNA
SCHEMBL5639641 0.87 LMNA (0.57) ALDH1A1HSD17B10MAPTLMNAF10
SCHEMBL5640706 0.86 LMNA (0.50) PRMT5ALDH1A1HSD17B10LMNAF10
SCHEMBL5640624 0.85 LMNA (0.49) PRMT5ALDH1A1HSD17B10MAPTLMNA
SCHEMBL4594577 0.84 HSD17B10 (0.46) PRMT5ALDH1A1HSD17B10MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1667647-A4 MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2008-10-22 EP disclosed
US-7199149-B2 Monocyclic and bicyclic lactams as factor Xa inhibitors BRISTOL MYERS SQUIBB COMPANY (US) 2007-04-03 US disclosed
EP-1667647-A2 MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS Bristol-Myers Squibb Company (US) 2006-06-14 EP disclosed
US-20050107361-A1 Monocyclic and bicyclic lactams as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMANY 2005-05-19 US disclosed
WO-2005032468-A2 MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107361-A1 Monocyclic and bicyclic lactams as factor Xa inhibitors F2, F12, SPINT2 PRMT5 3111/4885ALDH1A1 2842/4885HSD17B10 1275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.